Glenmark Gives India the Push by Topping its Anti-Diabetes Drug
Whatever Glenmark wanted to prove by introducing Zitamed and ZIta, their new anti-diabetes drugs, they’ve definitely topped this season.
Mumbai-based Glenmark Pharmaceuticals introduced the two anti-diabetes drugs in aRs 3,000-crore lucrative anti-diabetes market dominated by multinationals The drugmaker, which is locked in a bitter patent infringement battle with US drug firm Merck Sharp and Dohme's (MSD) over these drugs, has managed to rake in Rs 16 crore in just eight months since it launched them, according to data available with All India Organisation of Chemists and Association (AIOCD).
In a sort of kickback, Glenmark has priced these drugs at a third of the price of its competitors. Win? We definitely think so. This move may not only rattle the existing market, but also multina...
